TheraRadar

Pharma Intelligence, Simplified

← All Targets

alpha 2 adrenergic receptor

1 drugs
Ophthalmology
Market Leader
SIMBRINZA
Novartis
2
approved indications
1
Approved Drugs
1
Companies
2
Indications
1
Therapeutic Areas
Unlock Full Target Intelligence PRO
Competitive landscape by company (1 companies)
All 1 approved drugs
Therapeutic area breakdown
Full indication list (2 indications)
Patent cliff analysis
Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo

Drugs by Company

Novartis 1 drug

By Therapeutic Area

Ophthalmology 1 drugs